Androgen deprivation therapy affects BCL-2 expression in human prostate cancer.
about
Loss of STK11 expression is an early event in prostate carcinogenesis and predicts therapeutic response to targeted therapy against MAPK/p38.Bcl-2 expression is a poor predictor for hepatocellular carcinoma prognosis of andropause-age patients.The role of intracrine androgen metabolism, androgen receptor and apoptosis in the survival and recurrence of prostate cancer during androgen deprivation therapy.Current role of neoadjuvant and adjuvant systemic therapy for high-risk localized prostate cancer.Molecular pathways in prostate cancer.Sensitisation to mitoxantrone-induced apoptosis by the oncolytic adenovirus Ad∆∆ through Bcl-2-dependent attenuation of autophagy.
P2860
Androgen deprivation therapy affects BCL-2 expression in human prostate cancer.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Androgen deprivation therapy affects BCL-2 expression in human prostate cancer.
@en
Androgen deprivation therapy affects BCL-2 expression in human prostate cancer.
@nl
type
label
Androgen deprivation therapy affects BCL-2 expression in human prostate cancer.
@en
Androgen deprivation therapy affects BCL-2 expression in human prostate cancer.
@nl
prefLabel
Androgen deprivation therapy affects BCL-2 expression in human prostate cancer.
@en
Androgen deprivation therapy affects BCL-2 expression in human prostate cancer.
@nl
P2093
P50
P356
P1476
Androgen deprivation therapy affects BCL-2 expression in human prostate cancer
@en
P2093
Carlo Bettocchi
Paolo Fuzio
Trabucco Senia
P304
P356
10.3892/IJO.2011.1140
P577
2011-07-22T00:00:00Z